Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ANK2

Gene summary for ANK2

Gene summary.

Gene information	Species	Human
	Gene symbol	ANK2
	Gene ID	287
	Gene name	ankyrin 2
	Gene Alias	ANK-2
	Cytomap	4q25-q26
	Gene Type	protein-coding
	GO ID	GO:0001508
	UniProtAcc	Q01484

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
287	ANK2	ATC13	Human	Thyroid	ATC	2.28e-36	7.42e-01	0.34
287	ANK2	ATC5	Human	Thyroid	ATC	7.88e-38	8.07e-01	0.34

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:000616418	Skin	cSCC	purine nucleotide biosynthetic process	73/4864	191/18723	1.28e-04	1.17e-03	73
GO:00705849	Skin	cSCC	mitochondrion morphogenesis	13/4864	21/18723	5.53e-04	4.05e-03	13
GO:00159362	Skin	cSCC	coenzyme A metabolic process	10/4864	18/18723	7.25e-03	3.44e-02	10
GO:00067672	Skin	cSCC	water-soluble vitamin metabolic process	24/4864	59/18723	9.59e-03	4.30e-02	24
GO:0009060112	Thyroid	PTC	aerobic respiration	126/5968	189/18723	7.07e-23	1.78e-20	126
GO:0006091112	Thyroid	PTC	generation of precursor metabolites and energy	252/5968	490/18723	8.24e-20	1.13e-17	252
GO:0045333112	Thyroid	PTC	cellular respiration	140/5968	230/18723	9.60e-20	1.26e-17	140
GO:0015980111	Thyroid	PTC	energy derivation by oxidation of organic compounds	176/5968	318/18723	2.67e-18	2.90e-16	176
GO:000734619	Thyroid	PTC	regulation of mitotic cell cycle	212/5968	457/18723	4.03e-11	1.44e-09	212
GO:0071496113	Thyroid	PTC	cellular response to external stimulus	158/5968	320/18723	4.12e-11	1.47e-09	158
GO:000726519	Thyroid	PTC	Ras protein signal transduction	162/5968	337/18723	3.16e-10	1.02e-08	162
GO:004477218	Thyroid	PTC	mitotic cell cycle phase transition	196/5968	424/18723	3.17e-10	1.02e-08	196
GO:0048545113	Thyroid	PTC	response to steroid hormone	158/5968	339/18723	8.10e-09	2.00e-07	158
GO:0031668113	Thyroid	PTC	cellular response to extracellular stimulus	120/5968	246/18723	2.13e-08	4.91e-07	120
GO:003052228	Thyroid	PTC	intracellular receptor signaling pathway	126/5968	265/18723	6.31e-08	1.31e-06	126
GO:0031669112	Thyroid	PTC	cellular response to nutrient levels	106/5968	215/18723	6.96e-08	1.44e-06	106
GO:001969327	Thyroid	PTC	ribose phosphate metabolic process	176/5968	396/18723	8.28e-08	1.70e-06	176
GO:000915028	Thyroid	PTC	purine ribonucleotide metabolic process	165/5968	368/18723	1.03e-07	2.05e-06	165
GO:19019908	Thyroid	PTC	regulation of mitotic cell cycle phase transition	138/5968	299/18723	1.44e-07	2.78e-06	138
GO:007252127	Thyroid	PTC	purine-containing compound metabolic process	182/5968	416/18723	1.92e-07	3.51e-06	182

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ANK2

SNV

Missense_Mutation

rs775323997

c.3094N>A

p.Glu1032Lys

p.E1032K

Q01484

protein_coding

deleterious(0)

probably_damaging(0.962)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

ANK2

SNV

Missense_Mutation

novel

c.6349N>A

p.Asp2117Asn

p.D2117N

Q01484

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.642)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

ANK2

SNV

Missense_Mutation

c.2728C>G

p.Leu910Val

p.L910V

Q01484

protein_coding

tolerated(0.07)

benign(0.135)

TCGA-A2-A0CT-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

ANK2

SNV

Missense_Mutation

rs754722115

c.4280N>A

p.Arg1427Gln

p.R1427Q

Q01484

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-A7-A4SC-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

ANK2

SNV

Missense_Mutation

rs367592943

c.5827G>A

p.Gly1943Arg

p.G1943R

Q01484

protein_coding

deleterious_low_confidence(0.01)

possibly_damaging(0.506)

TCGA-A8-A06T-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozole

ANK2

SNV

Missense_Mutation

c.4222N>A

p.Glu1408Lys

p.E1408K

Q01484

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ANK2

SNV

Missense_Mutation

c.7868N>A

p.Ser2623Tyr

p.S2623Y

Q01484

protein_coding

tolerated_low_confidence(0.83)

possibly_damaging(0.66)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ANK2

SNV

Missense_Mutation

novel

c.6215C>A

p.Ser2072Tyr

p.S2072Y

Q01484

protein_coding

tolerated_low_confidence(0.07)

benign(0.367)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ANK2

SNV

Missense_Mutation

novel

c.7594G>T

p.Gly2532Trp

p.G2532W

Q01484

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ANK2

SNV

Missense_Mutation

novel

c.8177C>A

p.Thr2726Asn

p.T2726N

Q01484

protein_coding

tolerated_low_confidence(0.51)

benign(0)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1